The data presented in this article are related to the research article entitled "Cyr61/CCN1 is involved in the pathogenesis of psoriasis vulgaris via promoting IL-8 production by keratinocytes in a JNK/ NF-κB pathway" (Pinru Wu, Gang Ma, Xianjin Zhu, Ting Gu, Jie Zhang, Yue Sun, Hui Xu, Rongfen Huo, Beiqing Wang, Baihua Shen, Xiangdong Chen, Ningli Li, 2016) [1]. Cysteine-rich 61 (Cyr61/ CCN1), a secreted extracellular matrix protein, is a novel proinflammatory factor. In this dataset skin samples from normal donors and psoriasis vulgaris patients were examined the expression of Cyr61 and IL-8 using immunohistochemistry. IMQ-induced psoriasis-like mice were treated with antiCyr61monoclonal antibodies (mAb).
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Value of the data
This data characterizes the distribution of Cyr61 expression in skin lesion of patients with psoriasis vulgaris.
These data could be used for developing improved strategy in the treatment of psoriasis.
Data
The dataset of this article provides information on the Cyr61 and IL-8 expression in skin lesion in psoriasis patients ( Figs. 1 and 2 ) and the change of the production of Cyr61 by specific siRNA in vitro and anti-Cyr61mAb in vivo (Figs. 3 and 4 ).
Experimental design, materials and methods

Immunohistochemistry analysis of Cyr61 expression
Normal and lesional skin from human donors and mice were fixed in 4% paraformaldehyde, embedded in paraffin and sectioned. For immunohistochemistry, skin samples from patients were stained with anti-Cyr61 mAb at a concentration of 1:200 followed by HRP conjugated goat antimouse secondary antibody [1, 2] 
RNAi knockdown of gene expression
Cyr61, IL-1β and TNF-α small interfering RNA (siRNA , Table S2 ; see Supporting information) were designed and synthesized at Shanghai Genepharma (Shanghai, China) and gene knockdowns were performed as previously reported [3] . HaCaT cells were cultured in 24-well plates. A transfection mixture of siRNA oligonucleotides and Lipofectamine 2000 reagent (Invitrogen, Carlsbad, CA, USA) in serum-free medium was added to medium-aspirated cells for 4 h. Then, the medium was replaced with complete DMEM containing 10% fetal bovine serum for additional 24 h incubation.
Establishment and treatment of IMQ-induced psoriasis-like skin inflammation model in mice
For induction of the psoriasis-like skin inflammation model, mice received a daily topical dose of 62.5 mg of IMQ cream (5%) (Aldara, 3M Pharmaceutical, UK) on the shaved back and the right ear, representing a daily dose of 3.125 mg of the active compound. Control mice were treated similarly of either anti-Cyr61 mAb 093G9 or control IgG1 (Millipore, Billerica, MA, USA) 2 days after IMQ treatment. After16 days later mice were sacrificed and skin samples were collected and inspected [4] . 
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Transparency data associated with this article can be found in the online version at http://dx.doi. org/10.1016/j.dib.2016.12.008. Fig. 4 . Symptoms in psoriasis-like mice treated with 093G9 were significantly inhibited by blocking Cyr61. The multilayer silvery white scales in the back skin and the incrassation of the ears were decreased after blocking Cyr61 expression. **P o 0.01.
